Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This study has been completed.
Study NCT00786201   Information provided by Centocor, Inc.

First Received on November 4, 2008.   Last Updated on December 28, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pulmonary Fibrosis
Additional conditions recognized in this trial
Fibrosis
Idiopathic Pulmonary Fibrosis
More general conditions related to this trial
Idiopathic Interstitial Pneumonias
Lung Diseases
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
Placebo
CNTO 888 1 mg/kg
CNTO 888 5 mg/kg
CNTO 888 15 mg/kg
Sponsors listed in this trial
Centocor, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services